The benefits of pramipexole selection in the treatment of Parkinson's disease. (Q38231222)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25038745%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

The benefits of pramipexole selection in the treatment of Parkinson's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25038745%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25038745%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

A Yekta Ozer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25038745%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

20 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25038745%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

published in

Neurological Sciences

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25038745%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25038745%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

1505-1511

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25038745%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25038745%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10072-014-1891-5

9 March 2020

exact match

0 references

cites work

A clinicopathologic study of 100 cases of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Update on the use of pramipexole in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

The behavioural effects of pramipexole, a novel dopamine receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Comparison of the Risk of Adverse Events with Pramipexole and Ropinirole in Patients with Parkinson???s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson's disease and controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Pramipexole for the treatment of early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Toxicity assessment of pramipexole in juvenile rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Pharmacological approaches to counter the toxicity of Dopa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Neuroprotection in Parkinson models varies with toxin administration protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Pre-clinical studies of pramipexole: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

The role of pramipexole in a severe Parkinson's disease model in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Binding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: a positron emission tomography study using 11C-FLB 457.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-014-1891-5

Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial

21 January 2018

1 reference

12 December 2020

Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen

1 reference

12 December 2020

Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.

1 reference

12 December 2020

Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice

1 reference

12 December 2020

Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.

1 reference

12 December 2020

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

1 reference

12 December 2020

Parkinson's disease: drug-induced psychiatric states.

1 reference

12 December 2020

A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group

1 reference

12 December 2020

Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion.

1 reference

12 December 2020